Key Takeaways AbbVie is advancing Rinvoq expansions, tavapadon and PVEK toward multiple potential product launches.Rinvoq label expansions across five indications could add roughly $2B to peak-year sales.Tavapadon and PVEK are under FDA review as AbbVie expands its pipeline via acquisitions.AbbVie (ABBV) has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic areas. The company’s pipeline spans immunology therapies, expanding oncology programs and innovat ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisi ...

Core Insights - The State Street Health Care Select Sector SPDR ETF (XLV) is a passively managed ETF launched on December 16, 1998, providing broad exposure to the Healthcare - Broad segment of the equity market [1] - XLV is the largest ETF in its category, with assets exceeding $40.99 billion, and aims to match the performance of the Health Care Select Sector Index [3] Fund Details - The ETF has an annual operating expense ratio of 0.08%, making it the least expensive option in the healthcare ETF space, with a 12-month trailing dividend yield of 1.56% [5] - The fund is fully allocated to the healthcare sector, with top holdings including Eli Lilly + Co (12.97%), Johnson + Johnson, and Abbvie Inc, which together account for approximately 57.14% of total assets [6][7] Performance Metrics - As of December 16, 2025, XLV has returned approximately 14.79% year-to-date and 12.45% over the past year, with a trading range between $128.77 and $158.77 in the last 52 weeks [8] - The ETF has a beta of 0.61 and a standard deviation of 13.38% over the trailing three-year period, indicating a medium risk profile [8] Alternatives - Other healthcare ETFs include iShares Global Healthcare ETF (IXJ) with $4.52 billion in assets and Vanguard Health Care ETF (VHT) with $17.53 billion, each with different expense ratios [11]

创新奖项将遴选出具有潜力的早期生物技术企业，并为入选企业提供价值50万元的创新支持服务包，包 括飞镖加速器的高标准实验室和办公空间、驻场研发团队支持以及投融资与产业路演对接，以及艾尔建 美学在研发、生产、质量与合规等方面的专业建议。 艾尔建美学副总裁、中国总经理丘汉华表示："我们不仅关注技术突破，更注重与本土化服务体系的适 配。'艾伯维中国创新奖'正是我们践行这一理念的平台——通过资源、专业与产业对接的支持，与中国 创新伙伴深度连接，共创可持续、可复制的中国创新模式。" 据介绍，在未来的发展中，艾尔建美学将持续秉持开放合作的态度，坚持全球统一的质量与科学标准， 支持本土高质量创新项目的培育与发展，为中国医美行业的高质量、可持续发展贡献长期力量。 本报讯(记者金婉霞)12月15日，艾伯维旗下全球医学美容领导企业艾尔建美学在上海举办"中国创新合 作日"，活动汇聚了来自医美产业界、投资界及上游创新领域的先锋力量，围绕中国医美创新趋势、研 发管线进展、商业化合作与产业投资等议题展开了深度交流。会上，艾尔建美学副总裁、亚太及中东非 洲地区总裁王炜表示："中国在全球美学产业的创新版图上，正发挥着前所未有的驱动作用。我们希 ...

Singapore investors often focus on local dividend plays like REITs and bank stocks, and with good reason. However, limiting your portfolio to a single market can constrain growth and expose you to localised risk. For those seeking global diversification and exposure to multi-national growth, here are three US dividend stocks that can add global resilience to your portfolio.AbbVie Inc. (NYSE: ABBV) – Diversified biopharmaceutical firm AbbVie is a global diversified biopharmaceutical company with a portfolio ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - The healthcare sector is anticipated to potentially rebound in 2026, with several attractive stocks identified for investment, including AbbVie, Eli Lilly, and Intuitive Surgical. AbbVie - AbbVie is recognized as a reliable dividend payer, boasting 54 consecutive payout increases, qualifying it as a Dividend King [3] - The company reported third-quarter revenue of $15.8 billion, reflecting a 9% increase year-over-year [4] - AbbVie's product portfolio includes key drugs such as Vraylar, Botox Therapeutics, Qulipta, Skyrizi, and Rinvoq, which are expected to drive future growth [6][8] - Skyrizi is projected to become the second best-selling drug globally by 2030, with estimated sales of $26.6 billion [7] Eli Lilly - Eli Lilly's third-quarter revenue reached $17.6 billion, marking a significant 54% year-over-year growth [9] - The company is leveraging tirzepatide, marketed as Zepbound and Mounjaro, to sustain its growth trajectory, alongside promising pipeline candidates like orforglipron [10] - Eli Lilly is diversifying its portfolio, with recent launches in oncology, including Jaypirca for mantle cell lymphoma and Inluriyo for breast cancer [13] - The company's strategic investments in artificial intelligence and other therapeutic areas position it favorably for future growth [14] Intuitive Surgical - Intuitive Surgical faces challenges from tariffs and increased competition, particularly from Medtronic's Hugo system [15] - Despite these challenges, the company maintains a strong economic moat with 10,763 da Vinci systems installed, which creates high switching costs for customers [16] - The da Vinci system has over two decades of clinical evidence supporting its effectiveness, allowing Intuitive Surgical to command significant pricing power [18] - The company is expected to benefit from label expansions and increased procedure volumes, which will enhance revenue and margins over time [19]

Core Insights - Building wealth through dividends requires a strategy that goes beyond simply chasing high yields, emphasizing the importance of meaningful current income and consistent dividend growth supported by sustainable business fundamentals [1] Group 1 - The path to wealth accumulation involves a combination of current income and dividend growth [1] - Sustainable business fundamentals are crucial for supporting dividend growth [1]

Core Insights - The "High Income DIY Portfolios" service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees [1][2] - The service offers a total of 10 model portfolios, including various strategies like buy-and-hold and rotational portfolios, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1: Portfolio Strategies - The service includes seven portfolios: three buy-and-hold, three rotational, and a conservative NPP strategy portfolio, focusing on low drawdowns and high growth [1] - The portfolios are categorized into two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy [1] Group 2: Investment Approach - The investment approach emphasizes a unique 3-basket strategy that targets 30% lower drawdowns and aims for a 6% current income with market-beating growth over the long term [2] - The service provides buy and sell alerts, as well as live chat for real-time support and guidance [2]

Key Points One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff. They both look reasonably valued and are solid dividend-paying corporations. 10 stocks we like better than AbbVie › Looking for great stocks to be had at a bargain? Even though broader equities have performed well this year, there are companies, particularly in sectors that haven't kept up with the res ...